PT1064018E - Utilizacao de dominios isolados de colagenio de tipo iv para modificar interaccoes celulares e teciduais - Google Patents

Utilizacao de dominios isolados de colagenio de tipo iv para modificar interaccoes celulares e teciduais

Info

Publication number
PT1064018E
PT1064018E PT99914112T PT99914112T PT1064018E PT 1064018 E PT1064018 E PT 1064018E PT 99914112 T PT99914112 T PT 99914112T PT 99914112 T PT99914112 T PT 99914112T PT 1064018 E PT1064018 E PT 1064018E
Authority
PT
Portugal
Prior art keywords
alpha
collagenic
domains
isolated type
tissue interactions
Prior art date
Application number
PT99914112T
Other languages
English (en)
Inventor
Billy G Hudson
Michael P Sarras Jr
Original Assignee
Univ Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas Medical Center filed Critical Univ Kansas Medical Center
Publication of PT1064018E publication Critical patent/PT1064018E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PT99914112T 1998-03-27 1999-03-26 Utilizacao de dominios isolados de colagenio de tipo iv para modificar interaccoes celulares e teciduais PT1064018E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7978398P 1998-03-27 1998-03-27
US10617098P 1998-10-29 1998-10-29

Publications (1)

Publication Number Publication Date
PT1064018E true PT1064018E (pt) 2004-12-31

Family

ID=26762432

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99914112T PT1064018E (pt) 1998-03-27 1999-03-26 Utilizacao de dominios isolados de colagenio de tipo iv para modificar interaccoes celulares e teciduais

Country Status (10)

Country Link
EP (1) EP1064018B1 (pt)
JP (1) JP2002509895A (pt)
AT (1) ATE274351T1 (pt)
AU (1) AU748751B2 (pt)
CA (1) CA2318432C (pt)
DE (1) DE69919684T2 (pt)
DK (1) DK1064018T3 (pt)
ES (1) ES2224627T3 (pt)
PT (1) PT1064018E (pt)
WO (1) WO1999049885A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
AU4187200A (en) * 1999-04-01 2000-10-23 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
AU783662B2 (en) * 2000-01-07 2005-11-24 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
CN100447155C (zh) * 2001-05-23 2008-12-31 中国科学院上海上海生命科学研究院 具有抑制内皮细胞生长活性的重组人内皮生长抑制蛋白
JP2005504037A (ja) * 2001-07-27 2005-02-10 ユニヴァースティ オブ カンザス メディカル センター Iv型コラーゲンnc1ドメイン六量体の結晶化構造
WO2004050125A1 (ja) * 2002-12-03 2004-06-17 Koken Co.,Ltd. 腫瘍細胞の増殖及び/又は浸潤の抑制剤
CA2955481A1 (en) * 2014-07-25 2016-01-28 Goldfinch Biopharma, Inc. Collagen iv replacement
CN119751647B (zh) * 2024-12-31 2025-08-12 江苏创健医疗科技股份有限公司 重组iv型胶原蛋白及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
JP3840262B2 (ja) * 1995-10-23 2006-11-01 ザ チルドレンズ メディカル センター コーポレイション 治療用の抗血管新生組成物および方法

Also Published As

Publication number Publication date
DE69919684T2 (de) 2005-09-15
CA2318432C (en) 2003-01-28
DK1064018T3 (da) 2004-11-29
ATE274351T1 (de) 2004-09-15
DE69919684D1 (de) 2004-09-30
CA2318432A1 (en) 1999-10-07
ES2224627T3 (es) 2005-03-01
JP2002509895A (ja) 2002-04-02
WO1999049885A2 (en) 1999-10-07
EP1064018B1 (en) 2004-08-25
WO1999049885A3 (en) 1999-12-09
AU748751B2 (en) 2002-06-13
AU3202599A (en) 1999-10-18
EP1064018A2 (en) 2001-01-03

Similar Documents

Publication Publication Date Title
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
DE68927523D1 (de) Modifikation der Domäne der Konstantregion der Antikörpern
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
DK0584082T3 (da) Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
ATE294504T1 (de) Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen
DK1007537T3 (da) Receptor-protein med betegnelsen 2F1
ES2235353T3 (es) Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
MEP8209A (en) Modified factor viii
ATE358718T1 (de) Integrin antagonisten
ATE398676T2 (de) Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
PT770088E (pt) Nova citoquina designada lerk-5
CU22997A3 (es) Proteína híbrida para la inhibición de la desgranulación de los mastocitos y su utilización
SE0301087D0 (sv) New monoclonal antibody
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
ATE335735T1 (de) Imidazolyl-cyclische acetale
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
BR0109655A (pt) Marcadores genéticos para caracterìsticas melhoradas de carne em animais
ATE254660T1 (de) Methode zur markierung von eukaryotischen zellen mittels verwendung von rezeptoren der zelloberfläche als marker
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
TR200002955T2 (tr) Antitümör aktivitesi olan spisülozin bileşimleri
ATE442161T1 (de) Botulinumneurotoxin-b-rezeptoren und ihreverwendung
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf